Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients
<p>Abstract</p> <p>Background</p> <p>Elderly patients with chronic kidney disease (CKD) are usually at a high risk of fractures due to both osteoporosis and CKD-mineral bone disease (MBD). A new marker is needed to prevent fractures and control CKD-MBD from the early to...
Main Authors: | Kanda Eiichiro, Yoshida Masayuki, Sasaki Sei |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-09-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2369/13/122 |
Similar Items
-
Fibroblast growth factor 23 and cardiovascular disease in patients with chronic kidney disease
by: Kosaku Nitta
Published: (2018-08-01) -
The Importance of Phosphate Control in Chronic Kidney Disease
by: Ken Tsuchiya, et al.
Published: (2021-05-01) -
The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort
by: Matthew J. Damasiewicz, et al.
Published: (2018-11-01) -
PATTERNS OF CHRONIC KIDNEY DISEASE – MINERAL BONE DISEASE AND ITS RELATIONSHIP WITH SOCIO-DEMOGRAPHIC FACTORS AMONG THE PATIENTS OF CHRONIC KIDNEY DISEASE UNDERGOING HEMODIALYSIS
by: Batool Butt, et al.
Published: (2021-01-01) -
Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort
by: Vervloet Marc G, et al.
Published: (2012-04-01)